• LAST PRICE
    1.5000
  • TODAY'S CHANGE (%)
    Trending Down-0.0550 (-3.5370%)
  • Bid / Lots
    1.3500/ 2
  • Ask / Lots
    1.5400/ 4
  • Open / Previous Close
    1.5300 / 1.5550
  • Day Range
    Low 1.4300
    High 1.5300
  • 52 Week Range
    Low 0.6203
    High 3.5400
  • Volume
    637
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Wednesday's close: 1.555
TimeVolumeIDXG
03:07 ET2001.5
03:09 ET4151.5
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesIDXG
Interpace Biosciences Inc
6.7M
-5.8x
---
United StatesCLOV
Clover Health Investments Corp
392.8M
-1.8x
---
United StatesALHC
Alignment Healthcare Inc
905.2M
-6.2x
---
United StatesPGNY
Progyny Inc
3.7B
61.9x
---
United StatesMOH
Molina Healthcare Inc
24.5B
21.8x
+12.22%
United StatesHUM
Humana Inc
42.1B
17.5x
+9.96%
As of 2024-03-28

Company Information

Interpace Biosciences, Inc. provides personalized medicine and offers specialized services along the therapeutic value chain from early diagnosis and prognostic planning to targeted therapeutic applications. The Company, through its Interpace Diagnostics, provides clinically useful molecular diagnostic tests and bioinformatics and pathology services for evaluating risk of cancer by leveraging the latest technology. It has five commercialized molecular tests and one test in a clinical evaluation program: PancraGEN, which is for the diagnosis and prognosis of pancreatic cancer from pancreatic cysts; PanDNA, which is a molecular version of PancraGEN that provides physicians a snapshot of a limited number of factors; ThyGeNEXT, which is for the diagnosis of thyroid cancer from thyroid nodules utilizing a sequencing assay; ThyraMIR v2, used in combination with ThyGeNEXT, for the diagnosis of thyroid cancer, and RespriDX, which differentiates lung cancer of primary versus metastatic origin.

Contact Information

Headquarters
Waterview Plaza Suite 310, 2001 Route 46PARSIPPANY, NJ, United States 07054
Phone
412-224-6100
Fax
302-636-5454

Executives

President, Chief Executive Officer, Director
Thomas Burnell
Chief Financial Officer
Christopher Mccarthy
Independent Director
Vijay Aggarwal
Independent Director
Joseph Keegan
Independent Director
Fortunato Rocca

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$6.7M
Revenue (TTM)
$38.3M
Shares Outstanding
4.3M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
0.62
EPS
$-0.26
Book Value
$-3.85
P/E Ratio
-5.8x
Price/Sales (TTM)
0.2
Price/Cash Flow (TTM)
33.9x
Operating Margin
4.04%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.